The prevention of cardiovascular disease (CVD) by using a polypill has gained increasing momentum as a strategy to contain progression of the disease. Since its initial conception just over a decade ago, only a handful of trials have been completed assessing the efficacy and safety of this innovative concept. The results of these trials have supported the viability of the polypill in CVD prevention and management, albeit with a few caveats, essentially related to the lack of evidence on the effect of the polypill to effectively reduce cardiovascular events. The polypill has the potential to control the global health epidemic of CVD by effectively reaching underdeveloped regions of the world, simplifying healthcare delivery, improving cost-effectiveness, increasing medication adherence, and supporting a comprehensive prescription of evidence-based cardioprotective drugs. Major trials underway will provide definitive evidence on the efficacy of the polypill in reducing cardiovascular events in a cost-effective manner. The results of these studies will determine whether a polypill strategy can quell the burgeoning public health challenge of CVD and will potentially provide the evidence to implement an effective, simple, and innovative solution to restrain the global CVD pandemic. (J Am Coll Cardiol 2014;64:613-21)
The administration of cardiovascular (CV) medications (e.g., statins, antihypertensive agents, antithrombotic agents) remains the most common medical intervention for secondary prevention of CVD, estimated to be responsible for one-half of the overall 50% observed reduction in mortality from coronary artery disease over the past 20 years in some Western countries (4) . This tremendous reduction in mortality has been achieved despite patients not receiving the most comprehensive, proven benefit of contemporary medical therapies.
Recent data highlight the massive treatment gap and room for improvement in secondary prevention on a global scale. The PURE (Prospective Urban Rural Epidemiology) study showed that among participants with a history of CHD or stroke, only 25% were taking antiplatelet drugs, 17% were taking beta-blockers, 20% were taking angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, and 15% were taking statins 5 years after their event (5) . In low-and middleincome countries (LMIC) within the same study, the use of these drugs was as low as 3%.
A recent meta-analysis of >375,000 patients estimated adherence to CV medications at 2 years at 57% (6, 7) .
Rates of compliance with lifestyle modification and adherence to prescribed medications are alarming. More than 50% of patients, on average, decide to abandon their prescribed treatment, and the objectives to improve habits (quit smoking, lose weight, or engage in physical activity) are met by an equally low or lower percentage (8) . Beyond the impact nonadherence has on individual health, it carries a huge economic cost because it is associated with a failure to achieve therapeutic goals, higher rates of hospitalization, and greater incidence of death. Reasons for nonadherence to pharmacological therapy are complex and have been studied in-depth (8) (9) (10) . Most of the reasons for suboptimal adherence can be grouped into 4 categories: patient-, illness-, provider-, and system-related factors (Central Illustration, Table 1 ).
Taken together, these considerations lead to ineffective CV prevention and a missed opportunity for reducing CVD. One novel strategy seeking to address adherence is the use of a fixed-dose combination (FDC) polypill. Incorporating the key medications necessary to reduce CV risk into a single, once-daily dose pill could increase use of an effective, inexpensive therapy, thereby lowering costs and improving treatment adherence (11) . The concept of the polypill approach was introduced more than a decade ago and has slowly progressed from a conceptual debate to a therapeutic reality. Some of the scientific community's initial skepticism was due to the sweeping proposal from Wald and Law (12) , who claimed that a polypill including 6 active components administered to every individual older than 55 years of age would reduce the incidence of CVD by >80%. This "vaccination approach" has never been tested in a large population, and its efficacy, potential adverse effects, and cost-effectiveness would need to be assessed. Subsequently, the indication of the polypill has been suggested in primary prevention, specifically in individuals without previous CVD, with no indication for statins or blood pressure (BP)-lowering drugs, but who are at an overall high risk of CV events. The efficacy of this strategy is currently being tested in 2 large randomized trials. Finally, this third approach, the so-called "substitution approach," would use the polypill in patients already taking cardioprotective drugs for secondary prevention. The rationale is straightforward: by improving adherence to treatment, availability, and efficiency, the polypill might serve as a strategy to improve risk factor control and ultimately decrease CV events on a global scale (13) . Several trials have tested the effect of this adherence approach, with promising results. To date, however, no large randomized controlled trial (RCT) has been conducted to study the effect of the polypill strategy on event recurrence.
CLINICAL DATA/ONGOING STUDIES
Evidence is available on the efficacy, safety, tolerability, and affordability of FDC polypills for the primary and secondary prevention of CVD. The investigators anticipated that the full-dose regimen would reduce the risk of CHD by 75%, and of stroke by 65% (19) , if this strategy was used in the primary prevention setting, but they stressed that a large RCT is required to prove this assertion.
The recently published UMPIRE (Use of a Multidrug
Pill In Reducing Cardiovascular Events) study was the first randomized trial designed to assess the long-term effect of a FDC strategy in improving patients' adherence to medication in CV prevention (20) . Adherence to medication in the polypill group was 85%, compared with 60% in the standard-care group (p < Castellano et al. Table 2 . Castellano et al. 
CHALLENGES AND FUTURE DIRECTIONS
There are impressive, potential benefits that come with the use of a polypill strategy in CV prevention.
Unfortunately, the use of a polypill for CV prevention is relatively novel, and although data from clinical trials are accumulating, the clinical question that remains to dissipate skepticism is whether the polypill, beyond improving adherence and risk factor control as surrogate markers, can significantly reduce CV events.
The polypill has its own share of controversy due to the initial, vaccination strategy proposed by Wald and Law (12) , which has never been proven and of which the safety and feasibility remain largely unknown. Skeptics also are concerned that patients will regard the polypill as an excuse to potentially replace efforts to promote healthy lifestyles. The reasoning is that if patients assume an overvalued outlook on the polypill that will protect them from exposure to all CV risk factors, they may feel that they have the freedom to adopt inappropriate lifestyles without consequences.
In this regard, the UMPIRE trial has provided direct randomized data demonstrating that people who knew they were taking a polypill showed no adverse effect on lifestyle measures, such as weight, exercise, or smoking (20) . whether it is a viable solution to an epidemic facing every country, race, and community. Gradually, the role of the polypill in CV prevention is being defined.
Further research of the polypill is needed, with the collective results having the potential power to change the face of health care across the world.
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